Bank Julius Baer & Co. Ltd Zurich Acquires 15,813 Shares of Amgen Inc. (NASDAQ:AMGN)

Bank Julius Baer & Co. Ltd Zurich lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 346,927 shares of the medical research company's stock after acquiring an additional 15,813 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.06% of Amgen worth $99,922,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. OFI Invest Asset Management bought a new position in shares of Amgen during the 3rd quarter worth $26,000. Briaud Financial Planning Inc bought a new position in Amgen in the 3rd quarter worth about $26,000. BOK Financial Private Wealth Inc. bought a new position in Amgen in the 4th quarter worth about $29,000. Providence Capital Advisors LLC bought a new position in Amgen in the 3rd quarter worth about $30,000. Finally, Planned Solutions Inc. bought a new position in Amgen in the 4th quarter worth about $30,000. Institutional investors own 76.50% of the company's stock.

Amgen Stock Down 1.3 %

Shares of NASDAQ AMGN traded down $3.63 during mid-day trading on Thursday, hitting $269.38. 1,792,738 shares of the stock traded hands, compared to its average volume of 2,827,451. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a market cap of $144.49 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 2.55 and a beta of 0.58. The stock has a fifty day moving average price of $275.77 and a 200-day moving average price of $281.55.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analysts' expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm's quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.09 earnings per share. Research analysts anticipate that Amgen Inc. will post 19.42 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.34%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen's dividend payout ratio is currently 72.06%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several analyst reports. UBS Group cut their target price on Amgen from $314.00 to $284.00 and set a "neutral" rating for the company in a research note on Wednesday, April 17th. TD Cowen cut their target price on Amgen from $370.00 to $360.00 and set a "buy" rating for the company in a research note on Wednesday, April 17th. The Goldman Sachs Group raised their price target on Amgen from $313.00 to $350.00 and gave the company a "buy" rating in a report on Wednesday, February 7th. Leerink Partnrs cut Amgen from an "outperform" rating to a "market perform" rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $329.00 price target on shares of Amgen in a report on Wednesday, April 3rd. Ten investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.